Optimizerx Sets Fourth Quarter And Full Year 2025 Financial Results Conference Call For March 5, 2026, At 4:30 P.M. ET
| Date: | Thursday, March 5, 2026 |
| Time: | 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) |
| Toll Free: | 1-844-825-9789 |
| International: | 1-412-317-5180 |
| Conference ID: | 10206362 |
| Call meTM Link: | $Y2FsbG1lPXRydWUmcGFzc2NvZGU9JmluZm89Y29tcGFueSZyPXRydWUmYj0xNg== |
| Call meTM Passcode: | 6586380 |
| Webcast: |
Please call the conference telephone number or log on to the web access link five minutes prior to the start time.
A replay of the call will remain available for 12 months via the investors section of the OptimizeRx website at .
About OptimizeRx
OptimizeRx is a leading healthcare technology company that's redefining how life sciences brands connect with patients and HCPs. Our platform combines innovative, AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood® audiences to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and direct to consumer (DTC) strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.
Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world's leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.
For more information, follow the Company on LinkedIn or X, or visit .
OptimizeRx Contact
Andy D'Silva, Chief Business Officer
...
Investor Relations Contact
Steven Halper
LifeSci Advisors, LLC
...

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment